Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

Jang, Sekwon, Powderly, John D., Spira, Alexander I. · Journal of Clinical Oncology · 2021